Breaking News Instant updates and real-time market news.

MDGL

Madrigal Pharmaceuticals

$101.39

-3.73 (-3.55%)

, VKTX

Viking Therapeutics

$7.94

-0.07 (-0.87%)

05:58
06/25/19
06/25
05:58
06/25/19
05:58

Madrigal Pharmaceuticals initiated with a Hold at Stifel

Stifel analyst Derek Archila initiated Madrigal Pharmaceuticals (MDGL) with a Hold rating and $126 price target, stating that he is positively biased heading into Phase 3 amid emerging evidence that point to the possibility resmetirom could demonstrate a benefit on fibrosis over time. However, he thinks the stock could be volatile around updates from competitors such as Viking Therapeutics (VKTX) and Genfit (GNFT) and sees few catalysts specific to Madrigal to drive shares up in the next 12-18 months, Archila tells investors.

MDGL

Madrigal Pharmaceuticals

$101.39

-3.73 (-3.55%)

VKTX

Viking Therapeutics

$7.94

-0.07 (-0.87%)

GNFT

Genfit

$20.19

-0.02 (-0.10%)

  • 25

    Jun

  • 26

    Jun

  • 27

    Jun

MDGL Madrigal Pharmaceuticals
$101.39

-3.73 (-3.55%)

04/10/19
SBSH
04/10/19
NO CHANGE
Target $200
SBSH
Buy
Madrigal shares have little takeover premium, says Citi
Citi analyst Joel Beatty sees the Phase 3 trial design confirmed by Madrigal Pharmaceuticals at the end of March as "derisking." The analyst believes there will be a growing appreciation toward using nonalcoholic steatohepatitis drugs with a strong metabolic component in most patients. Further, there's little takeover premium currently in Madrigal shares, which could lead to upside in the event that a NASH competitor is acquired, says the analyst. He keeps a Buy rating on Madrigal Pharmaceuticals with a $200 price target.
06/10/19
RILY
06/10/19
UPGRADE
Target $134
RILY
Buy
Madrigal Pharmaceuticals upgraded to Buy from Neutral at B. Riley FBR
B. Riley FBR analyst Mayank Mamtani upgraded Madrigal Pharmaceuticals to Buy from Neutral and raised his price target for the shares to $134 from $128. The analyst believes the company's nonalcoholic steatohepatitis programs are "uniquely designed for maximize success."
05/15/19
WBLR
05/15/19
NO CHANGE
WBLR
Outperform
Viking Therapeutics risk/reward symmetry skewed to upside, says William Blair
William Blair analyst Andy Hsieh reiterates an Outperform rating on Viking Therapeutics (VKTX) after hosting investor meetings the company's CEO Brian Lian. The analyst continues to view Viking's risk/reward symmetry as skewed to the upside, especially with the recent sector volatility and the "continued significant valuation gap" with competitor Madrigal Pharmaceuticals (MDGL). Viking is on track to file an investigational new drug application later this year to the FDA's Division of Gastroenterology and Inborn Errors Products, which would enable the company to initiate the Phase II biopsy-confirmed nonalcoholic steatohepatitis study, Hsieh tells investors in a research note.
05/15/19
SBSH
05/15/19
NO CHANGE
Target $186
SBSH
Buy
Madrigal Pharmaceuticals price target lowered to $186 from $200 at Citi
Citi analyst Joel Beatty lowered his price target for Madrigal Pharmaceuticals to $186 from $200 citing a lack of near-term catalysts but maintains a Buy rating on the shares. The analyst still believes there will be a growing appreciation toward using nonalcoholic steatohepatitis drugs with a strong metabolic component and he sees Madrigal's Phase 3 trial design as favorable. Further, there is little takeover premium currently priced into the stock, Beatty tells investors in a research note.
VKTX Viking Therapeutics
$7.94

-0.07 (-0.87%)

03/29/19
LEER
03/29/19
UPGRADE
LEER
Outperform
Viking Therapeutics upgraded to Outperform from Market Perform at SVB Leerink
04/11/19
HCWC
04/11/19
NO CHANGE
Target $31
HCWC
Buy
Viking Therapeutics data 'compelling' at low doses, says H.C. Wainwright
Viking Therapeutics reported additional results this morning from its 12-week Phase 2 data of the lower 5mg dose of VK2809 in patients with non-alcoholic fatty liver disease. The "compelling" results show "impressive" safety and efficacy at low doses, H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. Importantly, VK2809 at low doses is able to "significantly reduce" liver fat content in 12 weeks to an extent similar to the one demonstrated by the higher doses tested, says the analyst. He reiterates a Buy rating on Viking Therapeutics with a $31 price target.
04/18/19
HCWC
04/18/19
NO CHANGE
Target $31
HCWC
Buy
Viking bear thesis based on 'fears and alternative facts,' says H.C. Wainwright
Bear pressure on Viking Therapeutics is "winning by share performance metric," but it is based on "fears and alternative facts," H.C. Wainwright analyst Joseph Pantginis tells investors in a research note. He believes Viking's shares are not reflecting the "compelling data" delivered to date for VK2809, as well as VK5211. The "massive" short interest, currently about 45% of shares outstanding, has been putting "significant pressure on the shares following highly positive news events," says Pantginis. The analyst continues to believe VK2809 represents a potential best-in-class molecule that could "also benefit from the clear definition of regulatory paths and questions established by others." He reiterates a Buy rating on Viking Therapeutics with a $31 price target.
GNFT Genfit
$20.19

-0.02 (-0.10%)

05/14/19
HCWC
05/14/19
NO CHANGE
HCWC
H.C. Wainwright affirms Buy on Genfit after positive recommendation from DSMB
H.C. Wainwright analyst Ed Arce affirmed a Buy rating and $72 price target on Genfit after the company announced that the the Data Safety Monitoring Board, or DSMB, of the Phase 3 RESOLVE-IT trial of elafibranor for the treatment of NASH, or nonalcoholic steatohepatitis, had "rendered a positive recommendation for the trial's continuation without any changes. This 36-month safety review is the sixth planned review by the DSMB, and revealed no safety issues with elafibranor." The analyst estimates elafibranor's probability of success at 75% for NASH and 60% for PBC, and utilize a 11.5% discount rate, which he believes is "appropriate for a small-cap development stage biotech."
04/24/19
LEER
04/24/19
INITIATION
Target $58
LEER
Outperform
Genfit initiated with an Outperform at SVB Leerink
SVB Leerink analyst Pasha Sarraf started Genfit with an Outperform rating and $58 price target. The analyst's core thesis in obesity-induced metabolic liver diseases, including nonalcoholic fatty liver disease and nonalcoholic steatohepatitis, is the utility of combining therapies that provide metabolic, and anti-inflammatory/fibrotic benefits on a background of practical weight loss therapies. Genfit's elafibranor may become one of the first products entering the market that fits this thesis with reproducibly meaningful lipid and triglyceride lowering benefits, insulin sensitization and reduction of glycated hemoglobin, and impact on inflammatory hepatic pathology, Sarraf tells investors in a research note.
04/22/19
HCWC
04/22/19
NO CHANGE
Target $72
HCWC
Buy
Genfit price target lowered to $72 from EUR 105 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce lowered his price target for Genfit to $72 from EUR 105 citing the impact of the 24.5% share dilution from the company's recent global offering. The new target, however, still represents about 188% upside from current levels and an implied market capitalization of $2.8B, Arce tells investors in a research note. With Genfit's Nasdaq listing complete, investor focus sharpens on nonalcoholic steatohepatitis and primary biliary cholangitis, adds the analyst. He keeps a Buy rating on the stock.
06/11/19
PIPR
06/11/19
NO CHANGE
Target $8
PIPR
Overweight
Piper cuts CymaBay price target to $8 on 'worst case' results for NASH trial
Piper Jaffray analyst Tyler Van Buren said he did not anticipate that placebo would perform better than seladelpar in CymaBay Therapeutics' (CBAY) Phase 2b study of the drug for the treatment of nonalcoholic steatohepatitis. Calling the NASH trial results a "worst case scenario," Van Buren sees significant risk to the final 52-week data read-out and removed all expectations in NASH from his model. He said the data make seladelpar seem similar to Genfit's (GNFT) elafibranor, though seladelpar has not yet shown improvements in good cholesterol, glucose homeostatis, or insulin resistance. While Van Buren cut his price target on CymaBay shares to $8 from $30 based on the trial results, he keeps an Overweight rating on the shares given the sharp pullback this morning and the support he sees from the company's remaining cash and residual opportunity.

TODAY'S FREE FLY STORIES

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

16:20
07/19/19
07/19
16:20
07/19/19
16:20
Options
Closing CBOE SPX and VIX Index summary for July 19th »

The CBOE Volatility Index…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCBP

BCB Bancorp

$12.71

-0.09 (-0.70%)

16:17
07/19/19
07/19
16:17
07/19/19
16:17
Earnings
BCB Bancorp reports Q2 EPS 30c, consensus 30c »

Net interest margin was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Technical Analysis
NYSE market internals summary »

Volume was below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNXM

CNX Midstream Partners

$14.30

-0.205 (-1.41%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Hot Stocks
CNX Midstream Partners raises quarterly distribution 3.6% to 38.65c per unit »

CNX Midstream Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

TELL

Tellurian

$7.25

0.22 (3.13%)

16:16
07/19/19
07/19
16:16
07/19/19
16:16
Syndicate
Breaking Syndicate news story on Tellurian »

Tellurian files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:15
07/19/19
07/19
16:15
07/19/19
16:15
General news
Breaking General news story  »

Boston Federal Reserve…

ROKU

Roku

$106.83

-2.18 (-2.00%)

16:13
07/19/19
07/19
16:13
07/19/19
16:13
Conference/Events
Roku management to meet with Oppenheimer »

Bull/Bear Luncheon to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 07

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.